Evidence map›Paper›PMID 39972514›Full record

ArticleEuropean journal of medical research2025

MEK5-ERK5 pathway mediates mitophagy by regulating Nur77 to promote tumorigenesis of osteosarcoma cells.

Jianshu Wang, Jinxu Xue, Baijing Ma, Yanqi Zhu, Jing Li, Caiping Tian

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Translational cancer research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jianshu WangDepartment of Bone and Soft Tissue Oncology, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China.
Jinxu XueDepartment of Bone and Soft Tissue Oncology, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China.
Baijing MaDepartment of Medical Molecular Biology Research Center, Gansu Provincial Academic Institute for Medical Research, Xiaoxihu East Street, Lanzhou, 730050, China.
Yanqi ZhuDepartment of Bone and Soft Tissue Oncology, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China.
Jing LiDepartment of Bone and Soft Tissue Oncology, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China.
Caiping TianDepartment of Medical Molecular Biology Research Center, Gansu Provincial Academic Institute for Medical Research, Xiaoxihu East Street, Lanzhou, 730050, China. tiancp123@163.com.

Funding

Gansu Province health industry outstanding young talents and backbone talents project GSWSQN2023-16Gansu Province science and technology plan project 22JR5RA643
6 · The paper itself

Abstract

objectivesTo investigate the influence of MEK5/ERK5 pathway on mitophagy in osteosarcoma (OS), as well as the involved molecular mechanisms.

methodsThe overlapped genes of mitophagy-related genes from MSigDB database and DEGs between metastatic and primary OS groups from GSE32981 were identified. GSVA of mitophagy-related pathways between the metastatic and primary groups were analyzed. The relationships between Nur77 and mitophagy-related pathways, prognosis, immune infiltrating cells, immune response gene sets were investigated. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blotting were utilized to assess the expression levels of MEK5, ERK5, Nur77, PINK1, and Parkin. Cellular behaviors and mitochondrial potential were evaluated via CCK-8, Transwell assay and JC-1 staining.

resultsTotal 4 overlapped genes were obtained as mitophagy-related DEGs, including GABARAPL1, HIF1A, PINK1, and RB1CC1. The activity scores of 3 mitophagy-related pathways exhibited significant differences between metastatic and primary groups. Importantly, Nur77 was significantly negatively correlated with a mitophagy-related pathway (GOBP MITOPHAGY: R = - 0.48, P = 0.02). The Nur77 expression in metastatic group was remarkedly higher than that in the primary group (P < 0.001). Patients with high Nur77 expression had poor prognosis, with AUC values all above 0.615 in predicting 1-, 3-, and 5-year survival. In addition, Nur77 was closely related to numerous immune cells, including activated dendritic cells, activated mast cells and M0 macrophages, and immune response gene sets chemokines and cytokines (all P < 0.05). In addition, MEK5/ERK5 pathway is activated in OS, and Nur77 is overexpressed in OS, and MEK5/ERK pathway promotes Nur77 expression, tumorigenesis and mitochondrial function in U2OS cells. Cytosporone B implement significantly increased the tumorigenesis of U2OS cells in sh-MEK5 group, and inhibited the weaken in mitochondrial membrane potential caused by MEK5 downregulation, and reversed the protein levels of mitophagy markers PINK1 and Parkin in sh-MEK5 group.

conclusionsMEK5-ERK5 pathway mediates mitophagy by regulating Nur77 to promote tumorigenesis of OS cells. These findings offered promising therapeutic targets for OS.

Indexed as

Bone NeoplasmsCarcinogenesisMAP Kinase Kinase 5Mitogen-Activated Protein Kinase 7MitophagyNuclear Receptor Subfamily 4, Group A, Member 1OsteosarcomaCell Line, TumorGene Expression Regulation, NeoplasticHumansPrognosisSignal TransductionMAP2K5 protein, humanMAPK7 protein, humanMAP Kinase Kinase 5Mitogen-Activated Protein Kinase 7NR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1MEK5–ERK5 pathwayMitophagyNur77Osteosarcoma

Identifiers

PMID39972514
PMCPMC11837295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.